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ABSTRACT 
BACKGROUND: Gemcitabine (2',2'-difluorodeoxycytidi∩e) administration after resection of pancreatic cancer 
improves both disease-free survival (DFS) and overall survival (OS). Deoxycytidine kinase (dCK) mediates the 
rate-limiting catabolic step in the activation of gemcitabine. The authors of this report studied patient outcomes 
according to the expression of dCK after a postoperative gemcitabine-based chemoradiation regimen. 
METHODS: Forty-five patients with resected pancreatic adenocarcinoma received adjuvant gemcitabine based-
therapy in the context of multicenter phase 2 studies. Their tumors were evaluated retrospectively for dCK 
protein expression by immunohistochemistry. A composite score based on the percentage of dCK-positive 
cancer cells and the intensity of staining was generated, and the results were dichotomized at the median values. 
RESULTS: The median follow-up was 19.95 months (95% confident interval [CI], 3.3-107.4 months). The 
lymph node (LN) ratio and dCK protein expression were significant predictors of DFS and OS in univariate 
analysis. On multivariate analysis, dCK protein expression was the only independent prognostic variable (DFS: 
hazard ratio [HR], 3.48; 95% CI, 1.66-7.31; P = .001; OS: HR, 3.2; 95% CI, 144-7.13; P = .004). 
CONCLUSIONS: dCK protein expression was identified as an independent and strong prognostic factor in 
patients with resected pancreatic adenocarcinoma who received adjuvant gemcitabine therapy. The authors 
concluded that it deserves prospective evaluation as a predictive biomarker for patient selection. 
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Patients with pancreatic adenocarcinoma have a poor prognosis despite curative-intent surgical resection, with a 
5-year overall survival (OS) rate of approximately 20%. Randomized trials suggest that the outcome of these 
patients is improved by the administration of gemcitabine.1,2 Gemcitabine is a 2'2'-difluoro-2'-deoxycytidine 
nucleoside analogue that inhibits DNA replication and repair and is a prodrug that is phosphorylated by 
deoxycitidine kinase (dCK) to its mononucleotide in the rate-limiting step of its cellular anabolism. Subsequent 
nucleotide kinases convert gemcitabine monophosphate to its active metabolites, gemcitabine diphosphate and 
gemcitabine triphosphate.3,4 The de novo DNA synthesis pathway is blocked through inhibition of ribonucleotide 
reductase (RRM) by gemcitabine diphosphate.5 
In addition to its cytotoxic effect, gemcitabine is a potent radiosensitiser. Recent in vivo studies have confirmed 
these observations and have demonstrated significant tumor growth delay with the combination of gemcitabine 
and ionizing radiation in animal models.6-9 These results have prompted a variety of adjuvant clinical trials using 
gemcitabine in combination with radiation therapy.7-13 In the Radiation Therapy Oncology Group study RTOG 
9704,14 gemcitabine was compared with bolus 5-fluorouracil (5-FU) as adjuvant chemotherapy after pancreatic 
cancer resection. In that phase 3 study, all patients received radiation with a concurrent, continuous infusion of 5-
FU sandwiched between chemotherapy during 1 month (gemcitabine or 5-FU) before and 3 months of 
chemotherapy afterward. Specific to tumors located in the pancreatic head, patients in the gemcitabine group had 
a trend toward better median survival (20.5 months vs 16.9 months in the 5-FU group; P = .09). It is noteworthy 
that the authors of that study subsequently focused their attention on gemcitabine sensitivity and on human 
equilibrative nucleoside transporter 1 (hENT1), an equilibrative nucleoside transporter (NT) that is the primary 
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gatekeeper for intracellular uptake of gemcitabine. hENT1 protein expression has been associated significantly 
with improvements in OS and disease-free survival (DFS) in patients with pancreatic cancer who received 
gemcitabine, but not in patients who received 5-FU.15 That study demonstrated that hENT1 is a useful predictive 
biomarker rather than simply a prognostic biomarker. 
Recently, our team demonstrated that both hENT1 expression and human concentrative NT 3 (hCNT3) 
expression were predictive of patient outcomes in a cohort of patients with resected pancreatic adenocarcinoma 
who received an adjuvant combination of gemcitabine and radiation.16 We hypothesized that the level of dCK 
within pancreatic adenocarcinoma also may be a determinant of gemcitabine efficacy and may refine the 
identification of those patients who will derive a particular benefit from this therapy. For this reason, we 
investigated the expression of dCK and sought associations with patient outcomes in a series of patients with 
resected adenocarcinoma who were treated on adjuvant gemcitabine-based clinical trials. 
MATERIALS AND METHODS  
Patient Specimens 
Paraffin-embedded tissue specimens from 45 primary ductal adenocarcinomas of the pancreas were obtained 
from the Surgical Pathology archives of the Belgian centers that included patients in 2 phase 2 Belgian 
multicentric studies.11,12 For each patient, 1 representative block of the infiltrating primary carcinoma was 
selected. Clinicopathologic and treatment data were obtained for each patient from the medical records. The 
project was approved by the relevant institutional review boards. 
Adjuvant Treatment Plan 
Treatment was planned to start within 8 weeks after surgery. Each patient was assigned to receive 2 cycles of 
gemcitabine 1000 mg/m2 weekly as a 30-minute infusion for 3 of 4 weeks on Days 1, 8, 15, 29, 36, and 43. After 
a 1-week rest, chemoradiation was started. Gemcitabine 300 mg/m2 as a 30-minute infusion was given weekly 
for 5 consecutive weeks and was administered 4 hours before radiation. Patients received 40 gays (Gy) (n = 15) 
to 50.4 Gy (n = 30) according to trial design.11,12 
Immunohistochemistry 
Rabbit polyclonal antibodies were raised against a synthetic peptide corresponding to residues 246 through 260 
of the human dCK protein.17 Tissues on slides were deparaffinized in xylene and rehydrated in decreasing 
concentrations of ethanol to water. Endogenous peroxidase was quenched in 3% H2O2 for 10 minutes. Antigen 
retrieval was performed using the RHS-2 (Milestone Inc., Atlanta, Ga) Microwave Rapid Histoprocessor in high 
pH Target Retrieval Solution (Dako, Glostrup, Denmark) followed by rinsing in water for 10 minutes. Tissues 
were incubated with the dCK polyclonal antibody at a dilution of 1:1200 at 4°C overnight in a humidified 
container. Slides were washed 2 times in phosphate-buffered saline (PBS) for 5 minutes. For the secondary 
antibody, the Antirabbit EnVision+ System-HRP (Dako) was used to incubate the tissues at room temperature 
for 30 minutes. Slides were washed twice in PBS, and the tissues were incubated with 3,3',diaminobenzidine 
(Dako) for 3 minutes; then, the slides were rinsed in water for 10 minutes followed by a soak in 1% copper 
sulfate for 5 minutes. Hematoxylin was used to counterstain the tissues. The slides were dipped 3 times in 
saturated lithium carbonate and rinsed in water, and the tissues were dehydrated in increasing concentrations of 
ethanol and xylene, then coverslipped. Tonsil was used as a positive control. The primary antibody was replaced 
with PBS for the negative control. 
Evaluation of dCK Staining 
Quantitative scoring using light microscopy was performed by a single pathologist (R.L.) who was blinded to 
clinical characteristics and outcomes. Cytoplasmic and nuclear staining was scored separately. Cytoplasmic 
staining was used for the evaluation of dCK protein expression. Immunohistochemical results were scored only 
in invasive adenocarcinoma cells. Staining of dCK protein was assigned a score from 0 to 2 based on staining 
intensity (no staining = 0, weakly positive staining = 1, and strongly positive staining = 2). The percentage of 
adenocarcinoma cells stained at each intensity level was recorded for each specimen. A final score was 
determined by multiplying the intensity score and the percentage of the positive cells in the specimen, as 
described previously.16 Therefore, the weighted scores ranged between 0 and 200. 
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Statistical Methods 
DFS was calculated from the date of curative-intent radical resection to the date of first recurrence or last follow-
up, and OS was calculated from the date of surgery to the date of death or last follow-up. The Kaplan-Meier 
method was used to plot DFS and OS, and the log-rank test was used to compare curves. A Cox proportional 
hazards multivariate model was used to corroborate the association between clinical and pathologic factors and 
tumor expression of dCK related to the efficacy of adjuvant radiochemotherapy in terms of DFS and OS. 
Multivariate analyses used a step-down procedure based on the likelihood ratio test. A P value ≤0.1 in univariate 
analysis was required to consider the variable for multivariate analysis. Data were analyzed using the SPSS 
software package (version 10.0; SPSS, Inc., Chicago, Ill). Statistical significance was prespecified at P<.05. 
RESULTS 
Patient Treatment and Outcome 
In total, 45 patients who underwent curative (R0) resection for adenocarcinoma of the pancreatic head were 
studied. These included 23 men and 22 women. The median performance was 0 (range, 0-1), and the a median 
patient age was 58 years (range, 34-83 years). Characteristics of the study patients are listed in Table 1. 
Adjuvant chemoradiation regimens were tolerated well and were completed by 43 of 45 patients (95%). World 
Health Organization grade 3/4 hematologic toxicities were reported in 10 of 45 patients (21%), and grade 3/4 
nonhematologic toxicities were reported in 3 of 45 patients (7%). The median follow-up after surgery was 21.9 
months (range, 3.3-107.4 months). Overall, the median DFS and OS were 13 months (range, 1-107.4 months) 
and 21.9 months (range, 3-107.4 months), respectively. At the last follow-up, 30 patients had died of disease 
recurrence, and 15 patients remained alive. 
 
Table 1. Baseline Patient Characteristics 
Characteristic No. of Patients (%) 
Sex  
Men 23 (51.1) 
Women 22 (48.9) 
Median age [range], y 56 [34-83] 
Median ECOG PS [range] 0 [0-1] 
Tumor classification  
T1/T2 12 (26.6) 
T3/T4 33 (73.4) 
Lymph node status  
N0 13 (28.9) 
N1 32 (71.1) 
Greatest tumor dimension, cm  
<2.5 24 (53.3) 
≥2.5 21 (46.7) 
Median lymph node ratio [range] 0.2 [0-1] 
Median CA 19-9 level at diagnosis [range], IU/mL 49 [0.8-3327] 
Median delay between surgery and start of adjuvant RCT [range], d 47 [24-74] 
ECOG PS indicates Eastern Cooperative Oncology Group performance status; IU, International Unit; RCT, radiochemotherapy. 
 
dCK Immunostaining: 
Among the 45 resected pancreatic cancer samples, all tumor samples had detectable cytoplasmic labeling for 
dCK with heterogeneous staining intensity (intensity score, 1+ and/or 2+); staining intensity varied within some 
tumors and between individual tumors. Nuclear staining was observed in 25 of 45 samples (55.5%) and was 
restricted exclusively to carcinoma cells that exhibited high cytoplasmic intensity staining (score, 2+). Positive 
labeling also was observed within normal lymphocytes, acinar cells, and islets, although the most consistent 
labeling for dCK was noted within lymphocytes. Thus, lymphocytes served as a useful positive internal control 
for evaluating staining patterns in the neoplastic cells. 
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Only cytoplasmic immunostaining was considered for statistical analysis. We dichotomized dCK cytoplasmic 
staining based on the median staining score. By using this criterion, the cutoff score was 140, and patients were 
divided in 2 groups: 1) low dCK expression, with a staining score <140, and 2) high dCK expression, with a 
staining score ≥140 (Fig. 1, top). 
 
Figure 1. These charts illustrate (Top) disease-free survival (DFS) and (Bottom) overall survival according to 
deoxycitidine kinase expression. 
 
 
Correlation Between Patient Outcomes and dCK Expression  
Univariate analysis 
The results of univariate analysis are summarized in the Table 2. Both OS and DFS were associated significantly 
with dCK expression. The median OS was 13.2 months (95% confidence interval [CI], 5.7-20.7 months) for 
patients with low dCK expression and was not reached during follow-up for patients with high dCK expression 
(hazard ratio [HR], 3.44; 95% CI, 1.60-7.44; P = .0008) (Table 2; Fig. 1, bottom). Similarly, the 3-year survival 
rate was 27.1% ± 9.5% versus 52.2% ± 10.4% (P = .03) for the low and high dCK expression groups, 
respectively. DFS also was longer in patients who had high dCK expression compared with patients who had 
low dCK expression (HR, 3.61; 95%CI, 1.74-7.75; P = .001; median DFS: low dCK expression, 6.3 months 
[95%CI, 2.9-9.6 months]; high dCK expression, 46.8 months [95%CI, 38.6-77.5 months]; P = .0003) (Table 2; 
Fig. 1, bottom). 
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Table 2. Univariate Analysis of Overall and Disease-Free Survival 
 OS DFS 
Variable OR (95% CI) P OR (95% CI) P 
Age, y     
<56, n=22 1.00    
≥56, n=23 1.23 (0.61-1.47) .31 1.19 (0.69-1.27) .18 
Sex     
Women, n=22 1.00  1.00  
Men, n=23 1.21 (0.76-1.43) .45 1.12 (0.84-1.52) .51 
ECOG PS     
0, n=40 1.00  1.00  
1, n=5 1.09 (0.76-1.62) .63 1.15 (0.69-1.74) .72 
CA 19-9 at diagnosis, lU/mL     
<49, n=23 1.00  1.00  
≥49, n=22 1.82 (0.86-3.85) .14 1.57 (0.78-3.18) .23 
Greatest tumor dimension, cm     
<2.5, n=24 1.00  1.00  
≥2.5, n=21 1.88 (0.94-3.73) .07 1.81 (0.87-3.70) .10 
Lymph node metastasis     
No, n=13 1.00  1.00  
Yes, n=32 1.80 (0.73-4.46) .19 1.59 (0.71-3.57) .26 
Lymph node ratio     
<0.2, n= 22 1.00  1.00  
≥0.2, n=23 2.01 (0.94-4.24) .06 1.81 (0.89-3.64) .11 
dCK expression     
High, n=23 1.00    
Low, n=22 3.44 (1.60-7.44) .002 3.61 (1.74-7.51) .001 
OS indicates overall survival; DFS, disease-free survival; ECOG PS, Eastern Cooperative Oncology Group performance status; dCK, 
deoxycytidine kinase. 
 
Table 3. Overall Survival and Disease-Free Survival Multivariate Analysis 
Variable OR 95% CI P 
DFS    
Lymph node ratio    
<0.2, n= 22 1.00   
≥0.2, n=23 1.46 0.69-3.06 .284 
Greatest tumor dimension, cm    
<2.5, n=24 1.00   
≥2.5, n=21 1.64 0.82-3.28 .16 
dCK expression    
High, n=23 1.00   
Low, n=22 3.61 1.74-7.51 .001 
OS    
Lymph node ratio    
<0.2, n= 22 1.00   
≥0.2, n=23 1.53 0.68-3.41 .299 
Greatest tumor dimension, cm    
<2.5, n=24 1.00   
≥2.5, n=21 1.60 0.83-3.73 .206 
dCK expression    
High, n=23 1.00   
Low, n=22 3.45 1.60-7.44 .002 
OR indicates odds ratio; CI, confidence interval; DFS, disease-free survival; dCK, deoxycytidine kinase OS, overall survival. 
 
 
Published in : Cancer (2010) 
Status : Postprint (Author’s version) 
 
Multivariate analysis 
A multivariate model was used to identify independent prognostic factors. The model included all 
histopathologic variables that had significant prognostic value in univariate analysis (greatest tumor dimension, 
lymph node ratio) (see Table 2) and the dCK abundance value. This analysis revealed that dCK abundance was 
the only independent risk factor for death (OS: HR, 3.61; 95%CI, 1.74-7.51; P = .001) and was the sole 
independent risk factor for recurrence (DFS: HR, 3.22; 95%CI, 1.56-6.65]; P = .002) (Table3). 
 
DISCUSSION 
Although evidence is emerging for the benefit of postoperative gemcitabine in the setting of resected pancreatic 
adenocarcinoma, such treatment carries some toxicity and is not without financial costs. Means with which to 
predict which patients are most likely to benefit from such treatment are needed, and determining the mediators 
of gemcitabine resistance may facilitate further improvements in patient outcomes. Recently, it was 
demonstrated that immunohistochemical assessment of the NT protein hENT1 has predictive value of hENT1 
immunohisto-chemistry for assessing the benefit from gemcitabine adjuvant chemotherapy in patients with early 
stage pancreatic cancer.15 However, after intracellular entry mediated by NTs, several enzymes involved in 
gemcitabine metabolism, such as dCK, cytidine deaminase, RRM1, and RRM2, also may have a key role in 
altering intracellular disposition of the drug and determining response to gemcitabine. These proteins have had 
limited evaluation as biomarkers in pancreatic carcinoma. Single, small, retrospective, clinical studies have 
suggested the poor prognostic value of high levels of RRM1 or RRM2 gene expression and low deoxycytidine 
kinase protein expression in patients with pancreatic cancer who were treated with gemcitabine.18-20 
Our data demonstrate a strong and statistically significant correlation between low levels of dCK protein 
expression in pancreatic cancer and poor clinical outcomes after gemcitabine-based adjuvant therapy. This 
finding remained significant on multivariate analyses after adjusting for standard clinicopathologic prognostic 
factors. It is noteworthy that dCK protein expression was the only significant independent markers of DFS and 
OS and conferred better prognostic information than lymph node involvement, the lymph node ratio, and the 
greatest tumor diameter. These results suggest that, for resected pancreatic cancer patients who are treated with 
gemcitabine, dCK evaluation could provide additional and potentially more powerful information that is not 
provided readily by standard prognostic factors. Only 1 previous study evaluated the prognostic value of dCK 
expression in pancreatic adenocarcinoma.20 In a retrospective cohort of 32 patients who received gemcitabine 
(either as a single agent or in combination) for either metastatic or resected disease, the investigators reported 
low dCK expression was associated significantly with decreased OS. The results of our study, which was 
conducted in a homogeneous population of patients who received treatment in the context of prospective trials 
evaluating the adjuvant gemcitabine regimen, substantiate and enhance the results of that earlier report.20 
In our study, dCK immunostaining was predominantly cytoplasmic, although nuclear staining was observed in 
specimens that exhibited high levels of cytoplasmic dCK protein. This immunostaining pattern is consistent with 
previous reports.21,23 Furthermore, the reported literature supports a cytoplasmic cellular localization of dCK on 
the basis of immunochemistry, immunoblotting of cellular fractions, enzymatic activity studies, and kinetic 
isotope incorporation experiments.21-27 
Limitations of our current study include its retrospective nature and the lack of controls who did not receive 
gemcitabine. Consequently, the predictive value of dCK in gemcitabine-treated pancreatic carcinoma (ie, the 
ability to identify those patients most likely to benefit from gemcitabine) could not be assessed formally. 
In conclusion, dCK expression was identified as an independent prognostic factor in patients with resected 
pancreatic cancer who received gemcitabine-based therapy. In our efforts to guide treatment decision for patients 
with resected pancreatic cancer, we might define gemcitabine sensitivity and resistance better in an integrated 
analysis of the expression of dCK, hENT1, and hCNT3 in a larger cohort of similar patients, ideally within the 
context of a randomized controlled trial. In this manner, it may be possible to more precisely define those 
subgroups of patients who derive particular benefit from adjuvant gemcitabine and those patients who warrant 
the investigation of experimental therapies. 
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